Composition for treatment of tuberculosis

A pharmaceutical composition comprising a compound of formula

• wherein R1 is
• unsubstituted phenyl or phenyl substituted by one, two or three substituents selected from C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, C1-C6-alkylcarbonyl, C1-C6-alkylcarbonyloxy, C1-C6-alkylthio, nitro, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, pyrrolidino, piperidino, morpholino, C1-C6-alkylcarbonylamino, and halogen;
• unsubstituted 2-, 3- or 4-pyridyl or 2-, 3- or 4-pyridyl substituted by one or two substituents selected from C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, nitro, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, C1-C6-alkylcarbonylamino, and halogen;
• or
• unsubstituted indolyl or indolyl substituted by one or two substituents selected from C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, nitro, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, C1-C6-alkylcarbonylamino, and halogen;
• R2 is (CH2)n wherein n is 0, 1, 2, 3 or 4;
• R3 is (CH2)mR3A wherein m is 0, 1, 2, 3 or 4;
• R3A is CH3, CH(CH3)2, C(CH3)3, OCH3, OH, OR3B, C≡CH, C≡N, unsubstituted phenyl or phenyl substituted by one, two or three substituents selected from C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, C1-C6-alkylcarbonyl, C1-C6-alkylcarbonyloxy, C1-C6-alkylthio, nitro, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, pyrrolidino, piperidino, morpholino, C1-C6-alkylcarbonylamino, and halogen;
• unsubstituted 2- or 3-furanyl or 2- or 3-furanyl substituted by one or two substituents selected from C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, and halogen;
• or
• unsubstituted 2- or 3-thienyl or 2- or 3-thienyl substituted by one or two substituents selected from C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, and halogen;
• and wherein
• R3B is unsubstituted phenyl or phenyl substituted by one, two or three substituents selected from C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, C1-C6-alkylcarbonyl, C1-C6-alkylcarbonyloxy, C1-C6-alkylthio, nitro, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, pyrrolidino, piperidino, morpholino, C1-C6-alkylcarbonylamino, and halogen;
• A is selected from
• wherein—represents the bond to C(═X2)—R3 and → represents the bond to R2—R1;
• or A together with —C(═X2)—R3 forms a ring selected from
• wherein → represents the bond to R2—R1;
• X1 is O, S, NH, N(CH3) or CH2;
• and
• X2 is O, S or NH;
• and a compound of formula
• wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8, or —NH—N═CH—R9;
• R5 is hydrogen, C1-C6-alkyl, optionally substituted phenyl, optionally substituted pyridyl, or a sugar residue;
• R6 is hydrogen or C1-C6-alkyl, or R5 and R6 together with the N-atom to which they are bound are pyrrolidine, piperidine or morpholine;
• R7 is hydrogen, C1-C6-alkyl, optionally substituted phenyl, optionally substituted pyridyl, or a sugar residue;
• R8 is hydrogen or C1-C6-alkyl, or R7 and R8 together with the N-atom to which they are bound are pyrrolidine, piperidine or morpholine;
• and
• R9 is optionally substituted phenyl,
• wherein the sugar residue in R5 and R7 is L- or D-furanosyl selected from aldopentoses arabinose, lyxose, ribose and xylose of formula 3 below;
• L- or D-hexofuranosyl selected from aldohexoses allose, altrose, glucose, mannose, gulose, idose, galactose and talose of formula 4 below;
• L- or D-hexofuranosyl selected from ketohexoses fructose, psicose, sorbose and tagatose of formula 5 below;
• L- or D-pyranosyl selected from aldohexoses allose, altrose, glucose, mannose, gulose, idose, galctose and talose of formula 6 below;
• or
• L- or D-pyranosyl selected from ketohexoses fructose, psicose, sorbose and tagatose of formula 7 below;
• in which one, two, three or four hydroxy groups can be methylated, benzylated or acetylated, or one hydroxy group can be replaced by hydrogen, halogen, methylamino, ethylamino, or acetamido.